The global breast cancer liquid biopsy market size reached US$ 130.4 Million in 2023. Looking forward, the publisher expects the market to reach US$ 497.2 Million by 2032, exhibiting a growth rate (CAGR) of 16.03% during 2023-2032.
Breast cancer liquid biopsy refers to a non-invasive medical procedure that utilizes blood as a sample for the identification of tumor markers. It assists in evaluating the progression of breast cancer disease and detects Epidermal Growth Factor Receptor (EGFR) gene mutations that help clinicians in choosing the best course of action at the right time. Some of the common biomarkers that are used in this process include circulating tumor cells (CTC), extracellular vesicles, circulating tumor DNA, etc. Breast cancer liquid biopsy offers several benefits, including minimal invasiveness, characterization of new lesions, drug and therapeutic target identifications for cancer treatment, etc.
This, in confluence with the increasing number of government and private reimbursement policies for breast cancer biopsy and other related medical procedures, is creating a positive outlook for the market. Apart from this, numerous manufacturers are making significant investments in the introduction of advanced biopsy techniques that enables the enhancement of several aspects of breast cancer management, such as prediction of prognosis, early diagnosis of relapse, serial sampling, efficient longitudinal monitoring of disease progress and response to treatment, etc. Furthermore, the emerging trend of personalized therapeutics coupled with the widespread adoption of polymerase chain reaction (PCR) and next-generation sequencing (NGS) for cancer detection will continue to drive the global breast cancer liquid biopsy market in the coming years.
2. What is the expected growth rate of the global breast cancer liquid biopsy market during 2024-2032?
3. What has been the impact of COVID-19 on the global breast cancer liquid biopsy market?
4. What are the key factors driving the global breast cancer liquid biopsy market?
5. What is the breakup of the global breast cancer liquid biopsy market based on the product services?
6. What are the key regions in the global breast cancer liquid biopsy market?
7. Who are the key players/companies in the global breast cancer liquid biopsy market?
Breast cancer liquid biopsy refers to a non-invasive medical procedure that utilizes blood as a sample for the identification of tumor markers. It assists in evaluating the progression of breast cancer disease and detects Epidermal Growth Factor Receptor (EGFR) gene mutations that help clinicians in choosing the best course of action at the right time. Some of the common biomarkers that are used in this process include circulating tumor cells (CTC), extracellular vesicles, circulating tumor DNA, etc. Breast cancer liquid biopsy offers several benefits, including minimal invasiveness, characterization of new lesions, drug and therapeutic target identifications for cancer treatment, etc.
Breast Cancer Liquid Biopsy Market Trends:
The growing prevalence of breast cancer along with the escalating demand for non-invasive medical procedures is primarily driving the global breast cancer liquid biopsy market. In addition to this, the rising consumer awareness towards numerous benefits associated with the liquid biopsy technique, including quicker results, lower cost, minimal health risk, non-invasiveness, etc., is also augmenting the market growth. Moreover, various global organizations are conducting awareness campaigns to educate individuals about breast health and cancer diagnostic measures.This, in confluence with the increasing number of government and private reimbursement policies for breast cancer biopsy and other related medical procedures, is creating a positive outlook for the market. Apart from this, numerous manufacturers are making significant investments in the introduction of advanced biopsy techniques that enables the enhancement of several aspects of breast cancer management, such as prediction of prognosis, early diagnosis of relapse, serial sampling, efficient longitudinal monitoring of disease progress and response to treatment, etc. Furthermore, the emerging trend of personalized therapeutics coupled with the widespread adoption of polymerase chain reaction (PCR) and next-generation sequencing (NGS) for cancer detection will continue to drive the global breast cancer liquid biopsy market in the coming years.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global breast cancer liquid biopsy market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product services, circulating biomarker and end user.Breakup by Product Services:
- Reagent Kits
- Instruments
- Services
Breakup by Circulating Biomarker:
- Circulating Tumor Cells (CTCs)
- Cell-Free DNA (cfDNA)
- Extracellular Vesicles (EVs)
- Others
Breakup by End User:
- Reference Laboratories
- Hospitals and Physician Laboratories
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Biocept Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Fluxion Biosciences Inc., Guardant Health Inc., Illumina Inc., Menarini Silicon Biosystems (The Menarini Group), NeoGenomics Laboratories Inc., Qiagen and Sysmex Europe SE (Sysmex Corporation).Key Questions Answered in This Report
1. What was the size of the global breast cancer liquid biopsy market in 2023?2. What is the expected growth rate of the global breast cancer liquid biopsy market during 2024-2032?
3. What has been the impact of COVID-19 on the global breast cancer liquid biopsy market?
4. What are the key factors driving the global breast cancer liquid biopsy market?
5. What is the breakup of the global breast cancer liquid biopsy market based on the product services?
6. What are the key regions in the global breast cancer liquid biopsy market?
7. Who are the key players/companies in the global breast cancer liquid biopsy market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Breast Cancer Liquid Biopsy Market
6 Market Breakup by Product Services
7 Market Breakup by Circulating Biomarker
8 Market Breakup by End User
9 Market Breakup by Region
10 SWOT Analysis
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Biocept Inc.
- Bio-Rad Laboratories Inc.
- F. Hoffmann-La Roche AG
- Fluxion Biosciences Inc.
- Guardant Health Inc.
- Illumina Inc.
- Menarini Silicon Biosystems (The Menarini Group)
- NeoGenomics Laboratories Inc.
- Qiagen
- Sysmex Europe SE (Sysmex Corporation)
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 142 |
| Published | August 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 130.4 Million |
| Forecasted Market Value ( USD | $ 497.2 Million |
| Compound Annual Growth Rate | 16.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
